Can I Take Ketamine with an MAOI?

If you are currently taking an MAOI (phenelzine, tranylcypromine, isocarboxazid, or selegiline) for depression and considering ketamine therapy, the answer at Tovani Health is that you are not currently a candidate for our at-home ketamine program. This is an operational position about our specific treatment model, not a sweeping clinical claim that the combination is universally dangerous. The published literature on combining ketamine with MAOIs has not actually documented the catastrophic outcomes that the historical clinical caution would predict; the safety record in carefully monitored research and clinical settings has been reassuring. At-home unmonitored is a different setting from where that safety record was established, and we'd rather be honest about the limits of our model than stretch it. The page below explains the published evidence, why we still hold the position we do for at-home, and what the path looks like if and when an MAOI is being discontinued for other reasons.

What the published evidence actually shows

The historical caution about combining ketamine with MAOIs predicts two specific hazards: a serotonergic excess pathway leading to serotonin syndrome, and a sympathomimetic potentiation pathway where ketamine's transient catecholamine release combines with the MAOI's blockade of catecholamine breakdown to produce a hypertensive crisis. Both pathways are pharmacologically plausible. The question is whether they have actually been observed in the published clinical literature.

The most carefully focused study of this question is Veraart and colleagues' 2022 paper in the Journal of Clinical Psychiatry (PMID 36300995). It combined a systematic literature review covering 12 prior studies (totaling 39 patients who received ketamine while on an MAOI) with a new case series of 8 additional patients. The headline finding was direct: no signs of hypertensive crisis, no signs of serotonin syndrome, mean systolic blood pressure elevation of just 3 mm Hg (range minus 12 to plus 13), mean diastolic elevation of 1 mm Hg. The authors' conclusion was that "the results suggest that combined use of MAOIs and esketamine is less prone to severe side effects than presumed."

The earlier and broader Veraart 2021 systematic review on ketamine drug interactions (International Journal of Neuropsychopharmacology, PMID 34170315) specifically reviewed the MAOI question and reached the same conclusion: "No reports were found that confirmed the hypothesized risk of hypertensive crisis or serotonergic syndrome caused by the combination of MAOIs and ketamine." The two case reports they identified showed no relevant cardiovascular or hemodynamic changes. Their recommendation was that prescribing the combination is possible "but only with careful monitoring of vital signs."

It's worth being clear about what these findings do and don't establish. The studied populations are small and the cases were almost universally done in inpatient or research outpatient settings with continuous vital-sign monitoring, established intravenous access, and immediate medical response capacity available. The combination has not been studied at scale in at-home unmonitored ketamine programs because no responsible at-home program has offered this combination. The published safety record exists; it exists in a specific setting.

Where the "this combination is dangerous" clinical narrative came from

If the published evidence on ketamine with MAOIs is reassuring, why has the field consistently treated this combination as a hard contraindication? The narrative is largely an extrapolation from MAOI interactions with other drug classes where the harm is well-documented:

The MAOI plus serotonergic antidepressant interaction (SSRIs, SNRIs, TCAs, tramadol, certain triptans) has produced multiple documented serotonin syndrome cases, including fatalities. This is the basis for the 14-day washout requirement before switching between an MAOI and most serotonergic agents, and it's medically real and well-validated.

The MAOI plus tyramine (the "cheese reaction") interaction has produced documented hypertensive crises, including fatalities. Tyramine is an indirect sympathomimetic; its breakdown is normally handled by gut MAO-A. When MAO-A is inhibited, dietary tyramine reaches the systemic circulation and triggers norepinephrine release from sympathetic nerve terminals.

The MAOI plus direct sympathomimetic interaction (amphetamines, pseudoephedrine) has produced documented hypertensive responses, also potentially severe.

Ketamine causes transient catecholamine release through a different mechanism, and the theoretical concern was that this would behave like the tyramine or amphetamine interaction. Predicted: hypertensive crisis. Observed: not in the published series we have. The clinical caution was reasonable in advance of the data; the data, when it came, did not support the predicted harm.

This is an important distinction to make on a directory page that aims to be evidence-honest. We don't want to repeat the "death in case reports" framing that's been carried forward from MAOI-plus-other-drugs literature when the ketamine-specific case reports do not, in fact, contain those events.

So why are we still saying "not a candidate for at-home"?

The honest answer is that at-home unmonitored is not the setting where the safety record was established. Every patient in the Veraart 2022 case series was in a clinical or research setting with continuous vital-sign monitoring. Every prior case report involved similar monitoring. The combined safety record exists in a specific operational context: blood pressure cuffs, immediate medical staff, and rapid response capacity available.

At-home Tovani is structurally different. Our model places ketamine sessions in your home with a sober support person and a video check-in but without continuous BP monitoring, on-site clinical staff, or immediate medical response capacity. For most ketamine candidates this is exactly the right model: lower cost, more comfortable, equally effective for the conditions we treat. For the small subgroup of patients on active MAOI therapy, the absence of that monitoring infrastructure is a meaningful gap.

The position is operational, not a sweeping claim about ketamine plus MAOIs being inherently dangerous. We don't offer this combination in our at-home model because the model wasn't designed for it. A monitored clinic setting that has the infrastructure to manage rare BP spikes or any other unexpected reaction may reasonably offer this combination, and several research groups have demonstrated they can do so safely. If MAOI therapy is the right treatment for you right now and you want to add ketamine to your regimen, you'd be looking for a clinic-based or research-based program that has the monitoring layer we don't.

The post-washout pathway

Many patients on MAOIs come to consider ketamine therapy specifically because they are thinking about an MAOI taper. MAOIs are typically a later-line antidepressant choice (after first- and second-line treatments have been tried), so patients on them often have complicated treatment histories and may be looking for the next thing. If you and your prescribing psychiatrist are already planning to come off your MAOI for other reasons, the 14-day washout period after your last MAOI dose puts you in the eligible window for at-home ketamine at Tovani.

The 14 days is not arbitrary. It is the period required for monoamine oxidase enzyme activity to fully regenerate after irreversible inhibition by phenelzine, tranylcypromine, or isocarboxazid. Selegiline (oral and transdermal) follows the same washout standard at antidepressant doses. After this window, the underlying pharmacology that made the original concern theoretical is reset, and the combination no longer raises a question.

What we want to be careful not to do is influence your decision to discontinue your MAOI. MAOIs are highly effective antidepressants for many patients with treatment-resistant depression, and they remain in clinical use precisely because they work when other classes haven't. The decision to stay on or come off an MAOI belongs entirely between you and your prescribing psychiatrist. If you and that physician decide a taper is the right next step, we can coordinate timing so the 14-day washout completes before your first ketamine session.

Specific MAOIs we treat under this verdict

The verdict applies uniformly across:

Phenelzine (Nardil): irreversible non-selective MAOI. Standard 14-day washout.

Tranylcypromine (Parnate): irreversible non-selective MAOI. Standard 14-day washout.

Isocarboxazid (Marplan): irreversible non-selective MAOI. Standard 14-day washout.

Selegiline, oral (Eldepryl, Zelapar): selective MAO-B inhibitor at low doses (typically 5-10 mg/day for Parkinson's adjunct use), but at antidepressant doses (higher) the selectivity is lost. Treated as a full MAOI for ketamine purposes. 14-day washout.

Selegiline, transdermal patch (Emsam): the 6 mg/24-hour patch dose has a more favorable interaction profile than oral selegiline because it bypasses gut MAO-A and may not require strict tyramine dietary restriction. The underlying class concern about catecholamine release potentiation in an unmonitored setting still applies, and we treat patch Emsam the same as oral MAOIs at all dose levels. 14-day washout.

We do not currently differentiate by MAOI subtype or dose for our at-home program. The published safety record applies broadly across the class.

What happens at intake

If you contact Tovani while on an active MAOI, the intake process is direct:

We explain the position clearly, including the published-evidence honesty (the combination has been demonstrated safe in monitored settings, just not in ours).

We confirm the specific MAOI, dose, and indication. The verdict applies the same regardless of which agent you're on, but knowing the specifics helps the conversation.

We ask whether you have a planned MAOI taper, and if so, when. If a taper is already underway, we can plan ketamine intake around the 14-day post-discontinuation window.

We discuss the option of a monitored clinic-based or research-based ketamine program if you and your psychiatrist want to keep the MAOI on board. We don't operate one, but we can talk through what to look for in such a program.

We do not encourage MAOI discontinuation. If your MAOI is working for you, the right answer may be to stay on it and either skip ketamine or pursue it later when your clinical picture changes.

Bottom line

If you are on an active MAOI today, you are not a candidate for at-home ketamine at Tovani Health. This is because our model does not have the vital-sign monitoring infrastructure where the published safety record for this combination was established. It is not because the combination is inherently dangerous; the literature has not borne out the historical concern. A monitored clinic setting may reasonably offer this combination if the MAOI is what's working for you right now. A 14-day washout after MAOI discontinuation, made by you and your prescribing psychiatrist on its own merits, opens the at-home Tovani pathway when the timing is right.